
Before we talk about any kind of treatment, I want to be direct about the stuff that's on you, not me. It won't undo a prescription that's already changed, but it's real and it matters for what happens next.
Time outdoors is the biggest lever you have. The research keeps landing in the same place, somewhere around two hours a day outside is associated with meaningfully slower progression, and nobody is fully sure why (daylight exposure, less near work, probably both). Screen time is the other half of it, and the numbers are blunter than most parents expect. A recent research review found kids using smartphones more than four hours a day were progressing nearsightedness by roughly two-thirds of a diopter a year, and each additional hour of daily screen time was tied to about a 21% higher chance of developing myopia at all. That's not a scare stat, that's just what the data says.
So: outdoor time up, recreational screen time down, and the 20-20-20 rule for anything close-up (every 20 minutes, 20 seconds, 20 feet away) actually enforced rather than suggested once and forgotten. None of this absolves the rest of us from doing the work either.
If we've made those changes and the prescription is still climbing, or if the progression is fast enough that waiting isn't a great plan, that's when we're not just updating glasses anymore, we're talking about myopia control. It's a specific category of treatment aimed at slowing the eye's elongation, not just correcting what's already there.
There's actual news in this space worth knowing about. The FDA cleared a new lens called Stellest for kids ages 6 to 12 this past year, built with a ring pattern of tiny lenslets that refocus light at the edges of the retina (the mechanism isn't fully settled scientifically, but the clinical data is solid). Company data reviewed by the FDA showed about a 70% reduction in progression over two years in trials conducted abroad, with U.S.-based studies still underway to confirm those numbers hold here. We also have MiSight contact lenses, which we evaluate kids for starting around age 8 if they're mature enough to handle daily lens care, low-dose atropine eye drops, and orthokeratology (overnight corrective lenses) for specific situations like a kid who swims or plays contact sports.
In practice, most families start with whichever option fits their kid's actual life, not whichever sounds most advanced. A younger child or one who isn't ready to handle contact lens care does well starting with Stellest glasses. An older, more responsible kid who wants to ditch glasses for sports gets evaluated for MiSight or ortho-K. Atropine drops are often a good add-on when progression is fast regardless of which lens option we pick.
I want to be honest about what these do and don't promise. They slow progression, they don't reverse it, and they're not a guarantee your child's prescription never moves again. Some kids still progress despite doing everything right, and if that happens to you, it's not a sign you or your kid failed at something.
Once your child is on a myopia control plan, we don't wait a full year to see how it's going. We typically recheck at six months, since that gives us enough time to actually see a trend in either the prescription or the eye's length, rather than guessing. If progression is still too fast at that point, we adjust, sometimes that means adding atropine to a lens option, sometimes it means switching which lens they're in.
If your kid's prescription jumped again at their last exam, don't wait for the next annual visit to start this conversation. Bring it up at the front desk when you book, and we'll set aside time to actually talk through which option makes sense, not just update the glasses and send you on your way.